CLDN18 and gastric cancer: Of particular note, the latest versions of the NCCN (Version 2.2025 Gastric Cancer) and CSCO (Clinical guidelines for the diagnosis and treatment of gastric cancer, 2025) guidelines have incorporated CLDN18.2 targeted agents into their recommendations, providing a novel therapeutic option for GC treatment.